-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$16.00109.42% Upside
BioCryst Pharmaceuticals, Inc. Frequently Asked Questions
-
What analysts cover BioCryst Pharmaceuticals, Inc.?
BioCryst Pharmaceuticals, Inc. has been rated by research analysts at Barclays, Jefferies, Evercore ISI, Cowen & Co., Cantor Fitzgerald in the past 90 days.